Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancerMarion T. Weigel, Lesley‐Ann Martin|Breast Cancer Research|2012Cited by 43
Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivoLesley‐Ann Martin, Mitch Dowsett|Breast Cancer Research|2012Cited by 33
Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor–positive breast cancersRicardo Ribas, Lesley‐Ann Martin|Breast Cancer Research|2014Cited by 26
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancerSunil Pancholi, Lesley‐Ann Martin|npj Breast Cancer|2022Cited by 16